-
Front.aging neurosci-decreased exosomal acetylcholinesterase activity in plasma in patients with Parkinson's disease
Time of Update: 2022-10-19
The research team from the Seoul Veterans Health Service Medical Center in South Korea simultaneously tested the chromosomal markers of acetylcholinesterase (AChE) and α-syn, isolated exosomes from plasma samples from PD patients and healthy control group (HC) by ultracentrifugation, measured exosome AChE activity and α-syn levels, and explored their correlation with clinical parameters and their biomarkers.
-
Arthritis Res Ther: Targeted therapy is safe and effective for elderly patients with rheumatoid arthritis
Time of Update: 2022-08-16
. In recent years, with the improvement of life prognosis in elderly patients with rheumatoid arthritis (RA), the increase in the incidence of elderly-onset RA, and the increased cumulative risk of RA in elderly women, the number of elderly RA patients has increased .
-
Cell Research: Neuroprotective Small Molecule Agonists of NAD Biosynthetic Enzymes
Time of Update: 2022-05-11
Recently, the team of Wang Gelin and Tang Yefeng from the School of Pharmacy, Tsinghua University, aimed at the major needs in the field of population and health, targeting NAD metabolism regulation and neurodegeneration and other aging-related diseases, a new scientific frontier hotspot, through high-throughput drug screening and target structure-based analysis.
-
Seven long-acting microsphere preparations are on the way in the Nuggets 10 billion inhalation preparation market
Time of Update: 2022-04-24
After years of market cultivation, Livzon Group's innovative drug ilaprazole series products and leuprolide acetate microspheres for injection of high-barrier complex preparations have become large varieties of 1 billion yuan .
-
J Immunother Cancer: Efficacy and safety of infliximab ((infliximab) and vedolizumab (vedolizumab)) in the treatment of immune-mediated diarrhea and colitis (IMDC
Time of Update: 2021-12-03
immune Journal for ImmunoTherapy of cancer magazine published a related study result, The study is a two-center retrospective observational cohort study that collected and analyzed IMDC patients treated with SIT from 2016 to 2020 after the progress of steroid therapy .
-
2021 CSCO Expert Interview｜Professor Ma Jun: Hematological tumors are progressing rapidly, and there is a long way to go for standardized diagnosis and treatment
Time of Update: 2021-10-22
Professor Ma Jun has made great progress in leukemia, lymphoma, myeloma and other diseases of malignant hematological tumors in recent years .
This year, China approved two CAR-T therapies, Akilunza injection and Reki Orenza injection for the treatment of relapsed and refractory large B-cell lymphoma, bringing hope of disease cure for some lymphoma patients .
-
Coronavirus can gain pathogenic advantage by triggering programmed cell death｜Science Advances
Time of Update: 2021-06-30
. To fill the gap in this research, Hin Chu and colleagues first observed the MERS-CoV virus in cultured human lung tissue and the lungs of infected transgenic mice, and found that these viruses induce severe cell apoptosis .
-
Professor Qing Su: Interpretation of "Management of Patients with Undifferentiated Thyroid Carcinoma: 2021 ATA Guidelines" | 2021CDEF
Time of Update: 2021-06-01
(Recommendation level: strong; quality of evidence: weak) Guideline recommendation 16: For patients whose lesions were unresectable at the initial evaluation, radiotherapy and/or systemic therapy (chemotherapy or combined with BRAF/MEK inhibitors) make it possible for the tumor to be resected, It is recommended to reconsider surgical resection.
-
Nature Sub-Journal: The latest research reveals whether hypoxia is tumor suppression or tumor promotion
Time of Update: 2021-04-13
The results of the study showed that an immediate early transcription response was determined, strongly dependent on the kinase activity of HIF1A and its cofactor CDK8, including indirect inhibition of MYC targets, and was highly conserved among cancer types.
-
Aceh Pharmaceutical MDM2-p53 inhibitors in a joint Bcl-2 inhibitor Phase 2a clinical study was approved in China and the United States
Time of Update: 2020-12-13
APG-2575 is a new type of oral Bcl-2 selective small molecule inhibitor, by selectively inhibiting Bcl-2 protein to restore the tumor cell program death mechanism (apoptosis), so as to achieve the treatment of blood and solid tumors.
-
Cell Res: Confused with the new coronavirus, Westlake University/Fudan University has teamed up to design a new corona protein inhibitor
Time of Update: 2020-11-25
research team based on the design and transformation of the new coronavirus subject ACE2, built a variety of ACE2 triglomer proteins, of which T-ACE2 and the new coronavirus pyrethroid protein affinity reached KD-lt;1 pM, while greatly improving the virus inhibition activity.
-
Hengrui Pharmaceuticals SGLT-2 inhibitor Heng grease net declared the listing
Time of Update: 2020-10-25
the most approved SGLT-2 inhibitors, Ingle has the highest net market share, with global sales of about $3.4 billion in 2019, according to public data released by the Company.
first half of 2020, Engele's net global sales were nearly $2 billion.
-
30 years of new breakthrough! The first immuno-tumor drug to treat pee path cancer in China has been approved
Time of Update: 2020-08-18
Interviewed experts: He Zhixuan, Deputy Director of the Institute of Urology, Peking University, Peking University, The First Hospital, Director of Urology, Professor specializes in treatment: urolog
-
The light is covered by ALK. How can ROS1 inhibitors get out of their own future
Time of Update: 2020-07-29
ROS1 has been one of the most interesting targets in recent years, and has been studied in many tumor fields, especially in the most extensive field of lung cancer However, when it comes to ROS1, it w
-
UK NICE approves first mono-anti-Stelara targeting IL-12/IL-23 for treatment of ulcerative colitis
Time of Update: 2020-06-25
The National Institute for Health and Clinical Excellence (NICE) has approved Janssen's Stelaara (ustekinumab) for the treatment of adult patients with moderate to severe active ulcerative colitis
